This month, we discussed the technical but important and timely issue of how to ensure adequate funding for research and development (R&D) into new ways to prevent and treat TB. TB is the world’s biggest infectious killer disease, yet many of the ways we have to fight it are out of date and, with the rise of drug-resistant strains, increasingly ineffective. Investing in scientific research is vital, yet there is insufficient funding to ensure we have the tools we need to end TB and other neglected diseases by 2030.
Our expert speaker, Rachael Hore, Senior Policy Advocacy Officer at RESULTS, took us through some of the existing funding mechanisms for TB R&D, and why they could be at risk from Brexit. You can watch the conference call here (60 mins).